2-溴-N,N-二甲基乙胺氢溴酸盐 | 2862-39-7

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-溴-N,N-二甲基乙胺氢溴酸盐
• 中文别名: (2-溴甲基)二甲胺氢溴酸盐；2-(二甲氨基)溴乙烷氢溴酸盐；N,N-二甲胺基溴乙烷氢溴酸盐；N,N-二甲氨基溴乙烷氢溴酸盐
• 英文名称: 2-(dimethylamino)ethyl bromide hydrobromide
• 英文别名: β-dimethylaminoethyl bromide hydrobromide；2-bromo-N,N-dimethylethylamine hydrobromide；2-bromoethyl-N,N-dimethylamine hydrobromide；1-bromo-2-dimethylaminoethane hydrobromide；2-bromethyl-N,N-dimethylamine hydrobromide；N,N-dimethylaminoethylbromide hydrobromide；(2-bromoethyl)-dimethylamine hydrobromide；(dimethylamino)ethyl bromide hydrobromide；2-bromoethyldimethylammonium bromide；2-bromo-N,N-dimethylethan-1-amine hydrobromide；2-bromo-N,N-dimethylethanamine hydrobromide；2-bromoethyl(dimethyl)azanium;bromide
• CAS: 2862-39-7
• 化学式: BrH*C₄H₁₀BrN
• mdl: MFCD00040375
• 分子量: 232.946
• InChiKey: MFRUVSDIZTZFFL-UHFFFAOYSA-N

物化性质

• 熔点：
  188.5-188.9 °C(Solv: ethyl acetate (141-78-6); ethanol, 95% (64-17-5)(8:5))

计算性质

• 辛醇/水分配系数(LogP)：
  1.04
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  4.4
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：室温下密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-N,N-dimethylethylamine hydrobromide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-N,N-dimethylethylamine hydrobromide
CAS number: 2862-39-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H10BrN.BrH
Molecular weight: 232.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

N,N-二甲胺基溴乙烷氢溴酸盐可作为有机合成中间体和医药中间体使用，主要应用于实验室研发和化工生产过程。

反应信息

• 作为反应物：
  描述：

  2-溴-N,N-二甲基乙胺氢溴酸盐 在 trisodium thiophosphate 作用下， 生成 Thiophosphorsaeure-S-<2-dimethylamino-ethylester>
  参考文献：
  名称：

  Akerfeldt,S., Acta Chemica Scandinavica (1947), 1962, vol. 16, p. 1897 - 1907

  摘要：

  DOI：
• 作为产物：
  描述：

  N,N-二甲基乙醇胺 在 氢溴酸 作用下， 生成 2-溴-N,N-二甲基乙胺氢溴酸盐
  参考文献：
  名称：

  Amundsen; Krantz, Journal of the American Chemical Society, 1941, vol. 63, p. 306

  摘要：

  DOI：
• 作为试剂：
  描述：

  5-甲基-1-已炔 在 硫酸 、 硝酸 、 2-溴-N,N-二甲基乙胺氢溴酸盐 、 potassium carbonate 作用下， 150.0 ℃ 、101.33 kPa 条件下， 反应 21.84h， 生成 1-Methyl-5-(3-methylbutyl)pyrazol-4-amine 、 1-Methyl-3-(3-methylbutyl)-1H-pyrazol-4-amine
  参考文献：
  名称：

  [EN] HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS
  [FR] DÉRIVÉS HÉTÉROAROMATIQUES EN TANT QU'INHIBITEURS DE NIK

  摘要：

  本发明涉及对哺乳动物疗法和/或预防有用的药物，特别是对NF-κB诱导激酶（NIK - 也称为MAP3K14）的抑制剂，用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病以及自身免疫性疾病。

  公开号：

  WO2018002217A1

文献信息

• [EN] NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS 6-AMINO-QUINOLINONE ET DÉRIVÉS EN TANT QU'INHIBITEURS DE BCL6
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018108704A1

  公开（公告）日：2018-06-21

  The present invention encompasses compounds of formula (I), wherein the groups R1 to R5, X, Y and W have the meanings given in the claims and specification, their use as inhibitors of BCL6, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

  本发明涵盖了式(I)的化合物，其中基团R1至R5、X、Y和W具有权利要求和说明中给定的含义，它们作为BCL6的抑制剂的用途，含有这种化合物的药物组合物以及它们作为药物的用途，特别是作为治疗和/或预防肿瘤疾病的药剂。
• 氮(氧)杂环戊烷-2-酮(硫酮)类化合物、其药 物组合物、制备方法和用途
  申请人：中国科学院上海药物研究所

  公开号：CN103626713B

  公开（公告）日：2017-07-04

  本发明属于药物学领域，涉及式I所示的氮(氧)杂环戊烷‑2‑酮(硫酮)类化合物、其药物组合物、制备方法及其在制备治疗糖尿病及糖脂代谢药物中的用途，尤其是制备治疗Ⅱ型糖尿病的药物的用途。
• [EN] PYRROLE DERIVATIVES AS PLK1 INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLE EN TANT QU'INHIBITEURS DE PLK1
  申请人：SENTINEL ONCOLOGY LTD

  公开号：WO2018197714A1

  公开（公告）日：2018-11-01

  The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof. The compounds are useful in the treatment of cancers.

  这项发明提供了化合物的公式（3）：或其药用可接受的盐或互变异构体。这些化合物在治疗癌症方面是有用的。
• KINASE INHIBITORS
  申请人：CHIESI FARMACEUTICI S.P.A.

  公开号：US20170183345A1

  公开（公告）日：2017-06-29

  Compounds of formula (I) defined herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

  根据此处定义的公式(I)化合物是p38 MAPK抑制剂，并且作为抗炎剂在治疗呼吸道疾病等方面是有用的。
• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018071454A1

  公开（公告）日：2018-04-19

  Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供了Formula I的化合物：(I)或其药用可接受的盐或溶剂，其中A、B、X1、X2、X3、X4、环D、E、Ra、Rb、n和m的含义如规范中所述，它们是RET激酶的抑制剂，并且在治疗和预防可以用RET激酶抑制剂治疗的疾病中非常有用，包括与RET相关的疾病和紊乱。